Table 1 Participant demographics and immunomodulatory drugs.

Total participants

62

35

N/A

Age, median years (IQR)

63.0 (55.0–68.0)

64.0 (54.0–70.3)

ns^a

Sex, % female subjects (n)

84 (52)

66 (23)

0.045^b

First dose vaccine type

48 BNT162b2

5 mRNA-1273

9 ChAdOx1

23 BNT162b2

4 mRNA-1273

7 ChAdOx1

ns^b

Second dose vaccine type

44 BNT162b2

14 mRNA-1273

4 ChAdOx1

27 BNT162b2

6 mRNA-1273

1 ChAdOx1

ns^b

Third dose vaccine type

39 BNT162b2

12 mRNA-1273

18 BNT162b2

12 mRNA-1273

ns^b

Fourth dose vaccine type

18 BNT162b2

23 mRNA-1273

1 bivalent

6 BNT162b2

6 mRNA-1273

2 bivalent

ns^b

Days between dose 1 and dose 2 (median ± SD)

71.0 ± 20.2

72.0 ± 20.6

ns^a

Days between dose 2 and dose 3 (median ± SD)

152.5 ± 33.3

183.0 ± 27.5

 < 0.0001^a

Days between dose 3 and dose 4 (median ± SD)

119.0 ± 48.5

203.0 ± 67.5

0.0004^a

Steroids^c, % (n)

19 (12)

N/A

N/A

DMARDs^d, % (n)

79 (49)

N/A

N/A

TNF (tumor necrosis factor) and TNF receptor inhibitors^e, % (n)

40 (25)

N/A

N/A

Janus Kinase Inhibitors, % (n)

17 (11)

N/A

N/A

Costimulation inhibitor (Abatacept), % (n)

19 (12)

N/A

N/A

SARS-CoV-2 Infections, % (n)

24 (15)

14 (5)

ns^b